CD40-Binding Antibody Composition for Aggregation-Stable Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antibody drugs, such as anti-CD40 antibodies, are prone to degradation and aggregation due to physical or chemical influences during production, storage, and use, leading to reduced activity or loss of efficacy, and there is a need for therapeutic agents that can intervene in the CD40-CD40L interaction to block CD40 signaling in autoimmune diseases.
Innovation Solution
A pharmaceutical composition comprising a CD40-binding molecule, such as an anti-CD40 antibody or antigen-binding fragment, stabilized with specific buffers like histidine-hydrochloride or histidine-acetate buffers, and optionally an antibody-drug conjugate with a linker and drug moiety, is developed to enhance stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody drugs are used to block CD40 signaling, then therapeutic efficacy is improved, but stability during production and storage deteriorates due to degradation and aggregation
Solution Approach 1:
The patent introduces buffer systems (containing histidine, acetate, succinate, phosphate, citrate, tartrate, fumarate, glycylglycine, or their salts) as intermediary substances to stabilize the antibody drug. These buffers act as mediators between the antibody and environmental stressors, preventing degradation and aggregation while maintaining the antibody's therapeutic function against CD40 signaling.
Solution Approach 2:
The patent optimizes formulation parameters including pH (adjusted through various buffer systems), ionic strength, and composition ratios to enhance antibody stability. By changing these physical-chemical parameters, the antibody maintains its structural integrity and binding affinity during production, storage, and administration while preserving therapeutic efficacy.
2Stability of the object's composition
If CD40-binding molecules are stabilized with buffers, then stability is improved, but formulation complexity increases
Solution Approach 1:
The patent employs homogeneous buffer systems where a single buffering agent (or compatible combination) is used to maintain uniform pH and ionic conditions throughout the formulation. This approach achieves stable antibody preservation without introducing complex multi-component systems, thereby minimizing formulation complexity while maximizing stability.
3Reliability
If antibody drugs are used to intervene in CD40-CD40L interaction, then therapeutic effect is improved, but susceptibility to physical and chemical influences worsens
Solution Approach 1:
The patent incorporates buffer systems and stabilizing agents into the antibody formulation beforehand to create a protective environment. This prior cushioning prevents the antibody from being affected by physical and chemical stressors during production, storage, and administration, thereby maintaining its therapeutic effect against CD40-CD40L interaction without compromising stability.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
A composition of a CD40-binding molecule and pharmaceutical use thereof. Specifically, the composition comprises an anti-CD40 antibody or an antigen-binding fragment thereof or an antibody-drug conjugate and a buffer.